Shares of vTv Therapeutics Inc (NASDAQ:VTVT) have been assigned an average recommendation of “Hold” from the seven brokerages that are currently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.75.
VTVT has been the subject of several analyst reports. Zacks Investment Research raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Tuesday, January 22nd. Northland Securities reissued a “hold” rating and issued a $3.00 target price on shares of vTv Therapeutics in a research note on Wednesday, February 27th.
VTVT stock traded down $0.10 during trading on Thursday, hitting $1.58. The stock had a trading volume of 851,268 shares, compared to its average volume of 1,229,478. vTv Therapeutics has a 1-year low of $0.65 and a 1-year high of $6.09. The company has a market capitalization of $75.72 million, a price-to-earnings ratio of -2.29 and a beta of -3.78.
In related news, major shareholder Ronald O. Perelman acquired 815,217 shares of the company’s stock in a transaction dated Tuesday, January 29th. The stock was bought at an average price of $1.84 per share, with a total value of $1,499,999.28. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders have bought 3,260,868 shares of company stock valued at $5,999,997. Corporate insiders own 1.70% of the company’s stock.
An institutional investor recently raised its position in vTv Therapeutics stock. Barclays PLC grew its stake in shares of vTv Therapeutics Inc (NASDAQ:VTVT) by 366.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,000 shares of the biotechnology company’s stock after acquiring an additional 22,000 shares during the quarter. Barclays PLC owned about 0.07% of vTv Therapeutics worth $74,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.12% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Read More: 52-Week High/Low
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.